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Pilocytic astrocytoma is the most common central nervous sys-
tem (CNS) neoplasm in childhood, accounting for ~20% of all 
pediatric brain tumors. Tumor locations in our cohort reflect the 
fact that pilocytic astrocytomas occur throughout the CNS, with 
about half arising outside the cerebellum (Supplementary Fig. 1). 
Extracerebellar tumors are often surgically inaccessible, leading to 
chronic disease with multiple recurrences, visual and neurological 
impairment and/or side-effects of therapy1,4. Genetic alterations 
within the MAPK signaling pathway are a hallmark of this tumor, 
with KIAA1549-BRAF fusion being the most frequent event6–8. 
A smaller number of tumors harbor BRAF or KRAS point mutations, 
alternative BRAF-RAF1 fusions or germline NF1 mutations2. Pilocytic 
astrocytoma has therefore been hypothesized to represent a single-
pathway disease2. Previously, however, no MAPK pathway changes 
were identifiable in 15–20% of tumors (mostly non-cerebellar)2.
To investigate the full range of genetic alterations in pilocytic 
astrocytoma, we performed whole-genome sequencing of tumor and 
blood DNA from 96 affected individuals (Supplementary Table 1). 
Corresponding RNA sequencing data and data from mate-pair 
sequencing with larger inserts (for enhanced detection of structural 
rearrangements) were generated for 73 and 68 samples, respectively. 
The average somatic mutation rate was extremely low (<0.1 mutation 
per megabase), with a mean of 1.6 nonsynonymous single-nucleotide 
variants (SNVs) per tumor (range of 0–9; Supplementary Table 1), 
similar to the rate described in NF1-associated pilocytic astrocytomas9. 
The somatic mutation rate in our series was markedly lower than 
those recently reported for the malignant pediatric brain tumor 
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medulloblastoma10–12 and for several other pediatric solid tumors13. 
The average number of small insertion-deletion alterations (indels) 
affecting coding sequences was <1 per case. All coding somatic SNVs 
and indels are listed in Supplementary Table 2.
In line with other tumor types10,14,15, pilocytic astrocytomas had 
genome-wide mutation rates that positively correlated with the age 
of the affected individual (r = 0.42; P = 2.3 × 10−5, Pearson’s product- 
moment correlation; Supplementary Fig. 2a). The observed muta-
tions were predominantly cytosine-to-thymine transitions at CpG 
sites (likely arising from deamination of methylated cytosines), 
suggesting that the age-dependent increase in mutation frequency 
may largely be due to background processes occurring in progeni-
tor cells before tumorigenesis, as recently reported in leukemia15 
(Supplementary Fig. 2b).
Most of the known events activating the MAPK pathway were 
also found in our series, including KIAA1549-BRAF fusion variants 
(70 cases), a FAM131B-BRAF fusion16, 4 BRAFV600E mutations and 
1 BRAFins599T alteration (Supplementary Table 1). Three tumors were 
associated with neurofibromatosis type 1. This prevalence is lower 
than would be expected for prospective cohorts (5–10%), as material 
for biological studies from these typically optic pathway–associated 
tumors is limited. NF1 has been reported to follow a classical tumor 
suppressor model in pilocytic astrocytoma, with a somatic second hit 
in addition to a germline alteration9. This model also held true in our 
series (Supplementary Table 1).
Analysis of copy number and structural alterations using DNA 
and RNA sequencing identified four new BRAF fusions (Fig. 1 and 
Supplementary Fig. 3). As expected, all variants resulted in loss of the 
N-terminal regulatory region of BRAF. An RNF130-BRAF fusion derived 
from a reciprocal t(5;7)(q35;q34) translocation was seen in two cases 
(Fig. 1a), with single examples identified of CLCN6-BRAF, MKRN1-
BRAF and GNAI1-BRAF fusions (Supplementary Fig. 3a–c). Thus, 
non–KIAA1549-BRAF fusions comprise a notable minority of activating 
events, with BRAF seeming to be a promiscuous fusion partner. 
Another new BRAF alteration was identified in ICGC_PA65, result-
ing in a three-amino-acid insertion (p.Arg506_insValLeuArg, insVLR) 
in the interdomain cleft of BRAF—a structural region linked to 
BRAF activity17 and homodimerization18. Protein modeling pre-
dicted that the insertion of these residues stabilizes a dimeric form 
of BRAF (known to be active independent of RAS stimulation19) 
(Fig. 1b). Homodimerization was confirmed by immunoprecipi-
tation, and the BRAFinsVLR mutant increased extracellular signal– 
regulated kinase (ERK) phosphorylation as effectively as the 
BRAFV600E mutant (Fig. 1c,d).
New alterations in KRAS were also observed. ICGC_PA117 
and ICGC_PA142 both showed two distinct mutations (encoding 
p.[Glu63Lys]+[Arg73Met] and p.[Leu19Phe]+[Gln22Lys], respec-
tively). DNA and RNA sequencing data confirmed that both altera-
tions affected the same allele (Supplementary Fig. 4). Although there 
are reports of double KRAS mutations in entities such as colon can-
cer20, these typically involve at least one hotspot residue (codon 12, 
13 or 61) and often represent heterogeneous tumor subclones rather 
than two hits in one allele (although this has also been described; for 
example, see ref. 21). The alterations identified in our tumors did 
not encompass classical mutational hotspots, suggesting that further 
characterization of downstream effects is warranted.
All but one of the cerebellar tumors in our series harbored a BRAF 
fusion, with this one exception having a KRAS alteration. Nine of 
48 (19%) of the non-cerebellar tumors, however, lacked the above 
alterations. Further assessment of structural rearrangements iden-
tified two new gene fusions in a total of three samples, involving 
the region encoding the kinase domain of NTRK2 (also known as 
TrkB)—an oncogene implicated in the tumorigenesis of neuroblas-
toma, among other cancers22,23. The related NTRK1 and NTRK3 
genes have previously been shown to be activated by fusion events 
(for example, TPM3-NTRK1 in papillary thyroid cancer24 and 
ETV6-NTRK3 in multiple tumors25). The QKI-NTRK2 and NACC2-
NTRK2 fusions identified here were verified by PCR (Fig. 2 and 
Supplementary Fig. 3d). Both 5′ partners contained regions encoding 
dimerization domains and are therefore predicted to induce ligand-
 independent dimerization. Notably, N-terminal TrkB truncation has 
recently been shown to induce transformation of neural crest cells26. 
Figure 1 New BRAF alterations in pilocytic 
astrocytoma. (a) Schematic of the RNF130-
BRAF fusion gene in ICGC_PA112 resulting 
from a translocation between chromosomes 
5 and 7. A similar fusion was observed in 
ICGC_PA96. The cDNA sequence at the fusion 
breakpoint (dashed line) and resulting exon 
and protein structures are shown. A reciprocal 
fusion between RUFY1 (encoding RUN and 
FYVE domain–containing 1) and TMEM178B 
(encoding transmembrane protein 178B)  
on the derivative chromosome 5 in ICGC_PA112 
was also found to be expressed in RNA 
sequencing analysis (data not shown).  
RPM, reads per million; KD, kinase domain.  
(b) Computational modeling of two BRAF 
monomers (light and dark gray) with a ValLeuArg 
insertion (blue and magenta) between Arg506 
and Lys507 (green), as identified in ICGC_PA65 
(p.Arg506insValLeuArg, insVLR). Protein 
Data Bank (PDB) structure 4E26 was used as 
a template. Val600, a mutational hotspot, is shown in yellow. A new dimer interface is formed between the protomers, with hydrogen bonds formed 
between the new arginine side chains (dashed lines) and a hydrophobic interaction between the leucine side chains (magenta). (c) Protein blot analysis 
of NIH3T3 cells transfected with empty vector (EV) or with vector expressing wild-type (WT) BRAF, BRAFV600E or BRAFinsVLR. The newly identified 
BRAFinsVLR mutant results in greater phosphorylation of ERK1 and ERK2 (pERK1/2), with phosphorylation at a similar level to that seen with the 
known oncogenic BRAFV600E form. (d) Pulldown assay with immunoprecipitation (IP) of HA-tagged BRAFinsVLR, showing that this new mutant forms 



























































































































Nature GeNetics  VOLUME 45 | NUMBER 8 | AUGUST 2013 929
l e t t e r s
The downstream effects of TrkB activation are mediated, at least in 
part, via MAPK pathway activation27.
A second new recurrent alteration, namely, mutation of two 
hotspots (codons for Asn546 and Lys656) within the kinase domain 
of FGFR1, was seen in five tumors (Fig. 3a and Supplementary 
Table 3). FGFR1 is more commonly activated through amplification 
in tumors such as breast28 and lung29,30 cancer. Occasional FGFR1 
mutations have been observed in adult glioblastoma (GBM)31,32, a 
highly malignant astrocytoma, as have FGFR1-TACC1 or FGFR3-
TACC3 fusion genes33. Mutations in homologous codons in FGFR2 
and FGFR3 are commonly found in other tumor types, particularly 
bladder, skin and endometrial cancers (see the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database34). Both mutations result 
in midbrain hyperproliferation in developing chick embryos35. The 
p.Asn546Lys variant alters FGFR1 autophosphorylation, resulting 
in higher kinase activity and transforming potential36, whereas the 
p.Lys656Glu variant is also transforming in vitro37. Notably, the latter 
study suggested that fibroblast growth factor 2 (FGF2, also known as 
bFGF) ligand was necessary in addition to FGFR1 mutation to main-
tain neurosphere formation in vitro. Gene expression array data of 118 
pilocytic astrocytomas, including 66 from the present series, showed 
significantly increased FGF2 expression in pilocytic astrocytomas 
compared with 158 other astrocytic tumors38,39 or normal tissues40. 
This increase was not restricted to only FGFR1-mutant or wild-type 
tumors, suggesting that ligand-mediated pathway activation may 
have a general role in tumorigenesis (Fig. 3b). Immunohistochemical 
detection of phosphorylated FGFR1 showed strong, diffuse positivity 
in all seven pilocytic astrocytomas harboring an FGFR1 mutation 
for which material was available. No positivity was observed in 11 
tumors with wild-type FGFR1. All samples showed strong staining for 
phosphorylated ERK (Supplementary Fig. 5). Notably, ICGC_PA89 
harbored an alternative alteration in FGFR1 consisting of a ~4.5-kb 
internal tandem duplication (ITD) of the portion of the gene encod-
ing the kinase domain, reminiscent of the activating internal tan-
dem duplications of the FLT3 kinase observed in acute myeloid 
leukemia41 (Fig. 3c).
Further recurrent mutations were found in the phosphatase gene 
PTPN11 (also called SHP-2) encoding a RAS-MAPK–related adap-
tor protein (Fig. 3d). Both encoded alterations (p.Glu69Lys and 
p.Glu76Ala) were previously reported in juvenile monomyelocytic 
leukemia, which is frequently associated with SHP-2 activa-
tion42,43. Notably, both alterations were found in FGFR1-mutant 
tumors (ICGC_PA84 and ICGC_PA166), suggesting a cooperative 
role of these factors in tumorigenesis (Supplementary Table 3). 
Overexpression of mutant SHP-2 alone did not elevate the levels of 
phosphorylated ERK in vitro, whereas the two FGFR1 mutants, either 
alone or in combination with mutant SHP-2, upregulated the levels 
of phosphorylated ERK (Supplementary Fig. 6). This finding sup-
ports the hypothesis that PTPN11 mutation alone is insufficient for 
pilocytic astrocytoma development but may have a modifying role in 
FGFR1-mutant tumors. Of note, PTPN11 expression was higher in 
pilocytic astrocytomas compared with other astrocytomas or normal 
tissues (Fig. 3e), suggesting that this phosphatase has a broader role 
in the biology of this entity. An additional cohort of 45 non-cerebellar 
pilocytic astrocytomas, negative for KIAA1549-BRAF fusion, was 
screened for FGFR1 (exons 12 and 14) and PTPN11 (exon 3) muta-
tions. Nine cases harbored FGFR1 mutations encoding a p.Asn546 or 
p.Lys656 alteration, and one additionally carried a PTPN11 mutation 
encoding a p.Glu69Lys change (Supplementary Table 3), confirming 
our whole-genome sequencing findings. Germline PTPN11 muta-
tions are one of the causes of the hereditary developmental disorders 
Noonan syndrome44 and multiple lentigines syndrome (also known as 
LEOPARD syndrome)45. A few case reports have described pilocytic 
astrocytomas occurring in individuals with these syndromes46–49. 
Thus, together with NF1, there are three known ‘RASopathies’, char-
acterized by germline MAPK pathway mutations50, linked with pilo-
cytic astrocytoma tumorigenesis. In our germline sequencing data, 
however, NF1 was the only RASopathy-related gene disrupted at a 
higher frequency than in the 1000 Genomes Project (see URLs).
Notably, all of the pilocytic astrocytomas in our cohort harbored 
a MAPK pathway alteration. BRAF, FGFR1, KRAS and NF1 were 
the only genes found to be significantly mutated using the Genome 
MuSiC algorithm (see URLs; Supplementary Table 4). With the 
exception of FGFR1 and PTPN11, each case typically harbored only 
one pathway alteration (P < 0.0001, permutation test; Fig. 4). Together 
with the finding that BRAF kinase activation alone is sufficient to 
induce pilocytic astrocytomas in mice51,52, these data strongly support 
the concept of pilocytic astrocytoma as a prototypic single-pathway 
disease driven by a limited number of oncogenic hits (possibly only 
one in some cases; Supplementary Fig. 7).
One of the FGFR1-mutant tumors (ICGC_PA69) also had an 
H3F3A mutation encoding a p.Lys27Met alteration and somatic 
mutations of NF1—both of which are more commonly encountered 
in pediatric GBM5. Three experienced neuropathologists agreed on 
pilocytic astrocytoma histology for this case, although a diagnosis of 
GBM cannot be conclusively excluded, owing to limited material. By 
examining previous exome sequencing data for pediatric GBM5, we 
identified 3 of 48 samples (6%) with an FGFR1 mutation. Notably, all 
three harbored the same constellation of an H3F3A p.Lys27Met altera-
tion, a somatic NF1 alteration and FGFR1 activation (Supplementary 
Table 3). They were also wild type for TP53, which is mutated in 
most GBMs or diffuse intrinsic pontine gliomas5,53 with the H3F3A 
p.Lys27Met alteration. One tumor reported in a targeted sequenc-























Figure 2 NTRK2 is a new gene fusion target in pilocytic astrocytoma. 
Schematic of the QKI-NTRK2 fusion gene in ICGC_PA159 resulting from 
a translocation between chromosomes 6 and 9. A similar fusion was 
observed in ICGC_PA82. The cDNA sequence at the fusion breakpoint 
(dashed line) and resulting exon and protein structures are shown.  
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with an H3F3A p.Lys27Met alteration, an NF1 alteration and an 
FGFR2 p.Lys659Glu alteration (homologous to FGFR1 p.Lys656Glu), 
making a total of five cases with this combination. Gene expression 
analysis indicated that this tumor was likely a GBM previously mis-
classified as medulloblastoma. It is not currently clear why these alter-
ations occur in concert, and additional work will be required to assess 
their roles. One possibility is that NF1 mutation may mimic elevated 
PTPN11 expression, as activation of SHP-2 inhibits the recruitment 
of Ras GTPase–activating proteins (RasGAPs, including NF1) to the 
plasma membrane54.
All FGFR1-mutant tumors were extracerebellar, mostly in midline 
locations (Supplementary Table 3), suggesting a link between cell of 
origin and/or microenvironment with FGFR1-driven tumorigenesis. 
The H3F3A p.Lys27Met alteration is also associated with midline 
GBM39. Notably, FGFR1 has a role in neural stem cell self-renewal55 
and is essential for midline glial cell development56. This spatial cluster-
ing may also reflect differential sensitivity of distinct neural precursors 
to activating stimuli, particularly NF1 loss57,58. The type and timing of 
second hits (H3F3A or NF1 mutation) and/or the differentiation stage 
of the cell of origin may contribute to determining a fate of oncogene- 
induced senescence and slow growth (pilocytic astrocytoma)59,60  
versus aggressive malignancy with poor outcome (GBM).
In summary, this study has provided new insights into the tum-
origenesis of pilocytic astrocytoma. Each tumor harbored very few 
mutations, in keeping with generally benign behavior. Our findings 
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Figure 3 FGF pathway signaling  
molecules are recurrently altered in pilocytic  
astrocytoma. (a) Schematic of the domain  
structure of FGFR1, indicating the position and  
frequency of the hotspot alterations in pilocytic  
astrocytomas sequenced in the present study (including replication cases).  
Ig, immunoglobulin-like domain; TM, transmembrane domain; TK, tyrosine  
kinase domain. (b) Gene expression data for FGF2 indicating significantly  
elevated expression in pilocytic astrocytomas (red) compared with other  
astrocytic tumors (blue), normal cerebellum (black) and other normal  
tissues (green); P < 0.001, two-sided t test. The pilocytic astrocytomas with  
expression data that harbor FGFR1 alterations (four mutants plus FGFR1-ITD)  
are circled. Horizontal gray bars indicate mean expression values per group.  
PA, pilocytic astrocytoma; DA, World Health Organization (WHO)  
grade 2 diffuse astrocytoma; AA, anaplastic astrocytoma; K27, G34 and  
IDH1 GBM, glioblastoma carrying a mutation affecting Lys27 or Gly34 of  
H3F3A or IDH1, respectively; CBM, cerebellum. (c) Schematic of an additional  
alteration in FGFR1 identified in ICGC_PA89 comprising an internal tandem  
duplication of part of intron 10, exons 11–17 and part of exon 18 (boundaries highlighted by dashed lines).  
The duplicated amino acids are residues 478–820 (numbered according to the α A1 isoform), with an additional 40-residue linker sequence encoded 
by part of intron 10. The whole kinase domain is therefore duplicated in the resulting predicted protein (TK1′ and TK2′). (d) Schematic of the structure 
of SHP-2 (PTPN11), indicating the position and frequency of alterations in pilocytic astrocytomas sequenced in the present study. SH2, src homology 
2 domain; PTP, protein tyrosine phosphatase domain. (e) Gene expression data for PTPN11 indicating significantly elevated expression in pilocytic 
astrocytomas compared with other groups as defined in b; P < 0.001, two-sided t test. The pilocytic astrocytomas with expression data that harbor 









Figure 4 Summary of MAPK pathway alterations in pilocytic astrocytoma. 
An overview of MAPK pathway alterations identified in the 96 whole-genome 
sequencing cases included in the present study, indicating the mutual 
exclusivity of the majority of these hits (with the exception of ones 
affecting FGFR1 and PTPN11); P < 0.0001, permutation test on 10,000 
iterations. Each column represents one tumor sample. Red boxes indicate 
that a given alteration is present in this sample. The blue box represents 
FGFR1-ITD rather than a point mutation. The yellow box indicates a  
BRAF p.Glu451Asp alteration in a case with a KIAA1549-BRAF fusion  
(of unknown functional significance but included in the exclusivity 
testing). The black/red split boxes represent one germline and one somatic 
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driven by aberrant activation of the MAPK pathway. Most notably, 
however, we report new recurrent mutations in NTRK2, FGFR1 and 
PTPN11, which were mutually exclusive with other RAF and RAS 
changes. Combined with the observation of FGF2 and PTPN11 over-
expression, these results indicate upstream contributors to MAPK 
pathway activation in this entity. Emerging preclinical data suggest 
that BRAF inhibitors may trigger paradoxical activation in tumors 
harboring KIAA1549-BRAF fusions, that is, the majority of pilocytic 
astrocytomas61. Single-drug or combination therapy with FGFR, 
NTRK2 and/or MAPK/ERK kinase (MEK) inhibitors, several of which 
are currently in preclinical and clinical trials62–64, may therefore rep-
resent rational treatment options. BRAFV600E-specific agents may also 
be a logical choice for ~5% of patients. Finally, the identification of 
recurrent FGFR1 mutations in a subset of pediatric GBMs provides an 
opportunity for the therapeutic targeting of FGFR signaling in these 
clinically challenging brain tumors.
URLs. ICGC PedBrain Tumor Project, http://www.pedbraintumor.
org/; 1000 Genomes Project, http://www.1000genomes.org/; 
GenomeMuSiC, http://gmt.genome.wustl.edu/genome-music/0.2/
index.html; Oncotator, http://www.broadinstitute.org/oncotator/; 
R2 tool, http://r2.amc.nl.
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Sample collection. Informed consent and an ethical vote (Ethics Committee 
of the Medical Faculty of Heidelberg) were obtained according to ICGC guide-
lines. Tumor tissues were subjected to neuropathological review to confirm 
histology and tumor cell content.
DNA sequencing. Paired-end library preparation was conducted using 
Illumina v2 protocols. Genomic DNA (1–5 µg) was fragmented to an insert 
size of ~300 bp with a Covaris device, and size selection was performed using 
agarose gel excision. Mate-pair (long-range paired-end mapping) DNA library 
preparation was carried out using the v2 protocol from Illumina. Genomic 
DNA (10 µg) was fragmented to an insert size of 4.5 kb with a Hydroshear 
device, and size selection was performed. Deep sequencing was carried out 
with Illumina HiSeq 2000 instruments.
RNA sequencing. Twenty-three RNA sequencing libraries were prepared 
with purified polyA+ RNA fractions using strand-specific methods, follow-
ing dUTP-based protocols as described65, featuring cDNA fragmentation after 
mRNA priming with random hexamer (dN)6 and oligo(dT) primers. Six librar-
ies were constructed with a modified protocol whereby the polyA+ fraction 
was fragmented using RNA fragmentation reagents (Ambion, AM8740); first-
strand synthesis was then performed with random hexamers only (cDNA 
fragmentation was omitted). Fifty RNA sequencing libraries were prepared 
with a ribosomal RNA–depleted fraction. In brief, 0.2 µg of total RNA was 
prepared using the RiboZero Gold kit (Epicentre). The resulting RNA was fur-
ther processed following a previously described library preparation protocol66, 
starting at the fragmentation step (step 2). Sequencing (2 × 51 bp) was carried 
out on the HiSeq 2000 platform.
Mapping and analysis. Sequencing reads were mapped and aligned to the 
hg19 reference assembly as previously described10, using Burrows-Wheeler 
Aligner (BWA)67 (version 0.5), and were processed with SAMtools68 (version 
0.1.17) and Picard tools (version 1.61).
An in-house analysis pipeline based on SAMtools mpileup and bcftools68 
was used to detect SNVs and small indels. In addition to previously described 
filters to remove artifacts10, we excluded variants located in regions of low 
mappability or overlapping with the hiSeqDepthTop10Pct, Encode DAC 
Blacklisted Regions or Duke Excluded Regions tracks from the UCSC Genome 
Browser. High-confidence somatic SNVs were not allowed to overlap with any 
two of the following features: tandem repeats, simple repeats, low-complexity, 
satellite repeats or segmental duplications. In addition, the following heuristic 
criteria were required: (i) at least 5 tumor reads at the position; (ii) more than 
one variant read per strand or at least 5 variant reads in total and variant 
allele fraction of >0.1; (iii) at least 12 reads at the position in the matching 
control; (iv) less than 1 of 30 of the control reads supporting the variant; (v) less 
than 300 reads at the corresponding position in the control; and (vi) no non- 
reference, non-variant bases at the corresponding position in the control.
Indels were called with SAMtools mpileup and bcftools on reads with map-
ping quality of >20 and were scored in a similar way as SNVs. Overlap with 
tandem or simple repeats, however, was not penalized, as these elements are 
prone to indels owing to polymerase slippage. Because indel alignments in 
the matched control can be slightly shifted in comparison to the tumor or 
mismatches can be preferred over gaps, germline events can be falsely called 
as somatic. We therefore required not more than one mismatch or indel in the 
matching control within 20 bp of the indel identified in the tumor.
Tumor and matched control samples were also analyzed with Pindel 
(version 0.2.4h)69. Events in the tumor were only considered when supported 
by at least five reads and if the number of supporting reads divided by the 
maximum read depth at the left and right breakpoints was >0.05. The matched 
control sample was also analyzed by SAMtools mpileup at tumor indel posi-
tions and 10 bp up- and downstream of this position. Variants were classified 
as somatic if both Pindel and SAMtools mpileup did not call a multibase vari-
ant in the control sample. Only additional indels in RASopathy genes were 
reported from the Pindel analysis (owing to a high false positive rate); all other 
indels were called with SAMtools as described.
SNVs and indels were functionally annotated with RefSeq gene annota-
tions using ANNOVAR70 and Oncotator. For the identification of significantly 
mutated genes, we used high-confidence somatic SNVs and indels as input 
for Genome MuSiC71 (version 0.3), setting max-fdr to 0.05 in the genome 
music smg module. Substitution patterns of SNVs were evaluated in a sequence 
context of all 96 possible trinucleotides to assess mutational signatures72.
Integration of SNVs and indels with RNA sequencing data. Gene expression 
levels were calculated per exon according to reads per kilobase of exon model 
per million mapped reads (RPKM) using BEDTools73 and custom Perl scripts. 
Where available, candidate DNA variant positions were annotated with RNA 
information by generating a pileup of the DNA variant position in the RNA 
BAM file (Supplementary Table 2).
Structural rearrangement detection and verification. Rearrangements 
identified on the basis of paired-end data were detected using read-
depth analysis, CREST74, DELLY75 and manual inspection of sequenc-
ing reads. Rearrangements identified on the basis of mate-pair data 
were detected using DELLY and manual inspection of sequencing reads, 
as previously described10.
Structural variants were verified by PCR (details on conditions and primer 
sequences available upon request). PCR products were sent to GATC Biotech 
(Germany) for Sanger sequencing to confirm breakpoints.
Fusion transcript detection and verification. Fastq files from transcriptome 
sequencing were used for de novo annotation of fusion transcripts using the 
TopHat-Fusion76 and deFuse77 algorithms with standard parameters. Where 
neither algorithm detected fusions but whole-genome sequencing supported 
the presence of a fusion, we extracted corresponding transcriptome reads 
matching the theoretical sequence surrounding the predicted fusion border 
and then counted as fusion reads those where the entire 51-bp sequence was 
derived from the predicted fused exons.
Primers for the amplification of neighboring exons in normal (unfused) 
transcripts were tested in RT-PCR using total RNA from normal cerebellum 
(BioChain, lot B307003). Validated primers were used to amplify the nor-
mal transcripts (control) and fusion transcripts from tumor RNA using the 
SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase 
(Invitrogen). Details on PCR conditions and primer sequences are available 
upon request.
Computational protein modeling. A dimeric model of mutant BRAFinsVLR 
was produced with Modeller78 using the PDB structure 4E26 as a template. 
Ten models were produced, with the one having the lowest discrete optimized 
protein energy (DOPE) score shown in Figure 1b.
Expression array analysis. Affymetrix U133 Plus 2.0 expression array data 
for genes of interest were extracted from publicly available data sets via the 
R2 software tool and for additional cases on an early-access basis through col-
laboration with the Microarray Department of the University of Amsterdam. 
The MAS5.0 algorithm of the GCOS program (Affymetrix) was used for nor-
malization and the assignment of detection P values. Array quality was ensured 
by inspection of ACTB and GAPDH 5′-3′ ratios as well as the percentage of 
present calls.
Verification of SNVs and indels. All SNVs and indels in FGFR1, PTPN11, 
BRAF, KRAS, NF1 and H3F3A were verified by PCR followed by capillary 
(Sanger) sequencing. Additional variants were also verified in this way, as 
listed in Supplementary Table 2. The verification rate for SNVs was >98% 
and for indels was >70%. Alterations determined to be false are not included 
in Supplementary Table 2.
In vitro and protein assays. Coding sequences of BRAF, PTPN11 and FGFR1 
were cloned from normal brain cDNA (Stratagene) into a pcDNA3.1 vec-
tor encoding HA, Flag or AU1 epitope tags. Site-directed mutagenesis 
(QuikChangeII XL, Agilent Technologies) was used to generate constructs 
encoding BRAFV600E, BRAFinsVLR, SHP-2E69K, SHP-2E76A, FGFR1N546K and 
FGFR1K656E.
NIH3T3 mouse fibroblasts (Leibniz Institute German Collection of 



























in DMEM (Life Technologies) supplemented with 10% FBS (Life Technologies) 
and penicillin-streptomycin at 37 °C in 5% CO2. Cells were transfected using 
Lipofectamine 2000 diluted in Opti-MEM (Invitrogen) and switched to 
serum-free DMEM 24 h after transfection. After a further 24 h, cells were 
lysed in either RIPA buffer or RLT buffer (Qiagen). Protein electrophoresis 
was performed using 4–12% gradient NuPAGE Bis-Tris Precast Gels (Life 
Technologies) with transfer to a PVDF membrane. Antibodies for protein 
blotting, with detection using ECL (GE Healthcare Life Sciences), were as 
follows: antibody to ERK1/2 (rabbit polyclonal, Cell Signaling Technology, 
9102), antibody to phosphorylated ERK1/2 (rabbit monoclonal 20G11, Cell 
Signaling Technology, 4376), antibody to HA (rabbit monoclonal C29F4, Cell 
Signaling Technology, 3724), antibody to AU1 (rabbit polyclonal, Abcam, 
ab3401), antibody to DYKDDDDK (Flag) (rabbit polyclonal, Cell Signaling 
Technology, 2368), HRP-conjugated goat antibody to rabbit immunoglobu-
lin G (IgG) (Santa Cruz Biotechnology, sc-2004) and HRP-conjugated goat 
antibody to mouse immunoglobulin (Santa Cruz Biotechnology, sc-2005). 
All primary antibodies were used at a dilution of 1:2,000.
For coimmunoprecipitation experiments to assess BRAF dimerization, cells 
were washed twice in ice-cold PBS, scraped, pelleted and then lysed on ice in 
five pellet volumes of lysis buffer (50 mM HEPES, pH 7.5, 250 mM NaCl, 1 mM 
EDTA, 2.5 mM EGTA, 10% glycerol, 0.1% Triton X-100 and protease inhibi-
tors) with regular vortexing. Lysates were run through a QiaShredder column 
(Qiagen), centrifuged and transferred to a new tube. Anti-HA agarose slurry 
(8 µl; Thermo Scientific) was washed three times and then resuspended in 
20 µl of lysis buffer. Protein extract (50 µg) was added to the anti-HA slurry 
and rotated overnight at 4 °C. Finally, beads were pelleted, washed seven times 
in lysis buffer and resuspended in SDS sample buffer for protein blotting.
Immunohistochemistry. Immunohistochemistry was performed with an 
automated stainer (Benchmark XT, Ventana). Phosphorylated FGFR (Tyr653/
Tyr654) was detected using antibody PA5-12594 (Thermo Scientific) diluted 
1:50. Phosphorylated ERK1/2 (Thr202/Tyr204) was detected using antibody 
9101 (Cell Signaling Technology) diluted 1:100.
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